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tional studies as well as with reports on the age of onset of
psoriasis. The data may provide a basis for future studies on
health care utilization and cost of illness associated with psoriasis
in Germany.
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OBJECTIVES: To ﬁnd out the persistence degree (period of time
of continuous therapy with the drug prescribed) of glaucoma
patients treated with prostaglandin (latanoprost, bimatoprost,
and travoprost), or b-blocker (timolol) monotherapy.
METHODS: An observational and retrospective study was con-
ducted of a 24-month follow-up in 191 patients (from 4 centers),
to examine the time elapsed until patients’ withdrawal from
therapy. The required parameters were obtained from patients’
medical records. A descriptive analysis, a Kaplan-Meier survival
analysis, and a Cox regression model were used to determine
which was the drug related to a greater persistence degree, and to
detect variables signiﬁcantly inﬂuencing persistence in these
patients. RESULTS: In both the descriptive analysis and the
survival curves, latanoprost was associated with a higher persis-
tence degree in the glaucoma treatment: 81.6% vs. 22.9% for
bimatoprost, 65.4% for travoprost and 60.5% for timolol
(p < 0.0001). The persistence degree was signiﬁcantly inﬂuenced
by the following variables: the antiglaucoma agent used as mono-
therapy, with a six-fold higher risk of treatment withdrawal
during the follow-up period due to receiving travoprost instead
of latanoprost (p < 0.0001); and the age (p = 0.001). Even
though comorbidities did not indicated to be directly related to
persistence, their occurrence was related to age. The main
reasons for treatment withdrawal were lack of efﬁcacy and the
existence of intolerance and/or adverse events, signiﬁcantly supe-
riors in the bimatoprost group, 28.6% (p < 0.001) and 48.6%
(p < 0.001), respectively. CONCLUSIONS: Latanoprost shows a
higher persistence degree compared to travoprost, bimatoprost
and timolol in routine clinical practice, resulting in a better
control of IOP and lower associated costs, improving the health
care quality of glaucomatous patients and considerable resources
saving for the National Health System.
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OBJECTIVES: Our aim was to evaluate systematically the efﬁ-
cacy and safety of tacrolimus ointment for the treatment of
adults and children with atopic dermatitis (AD). METHODS:
Electronic and manual bibliographic searches were conducted to
identify relevant prospective randomised controlled trials
(RCTs). The primary outcome measures of interest included
treatment success measured by objective clinical scales and safety,
based on the incidence of adverse events. Meta-analyses were
conducted using a ﬁxed-effect model. RESULTS: Thirty RCTs
met the inclusion criteria. Comparator treatments included
topical corticosteroids (n = 14) and 1% pimecrolimus cream
(n = 5). Eight RCTs comparing tacrolimus with corticosteroids
(paediatric, n = 1593; adult, n = 2104) provided data for meta-
analysis. In 6/8 RCTs (75%), treatment with 0.1% or 0.03%
tacrolimus was superior to corticosteroid treatment (1% hydro-
cortisone acetate, 0.1% hydrocortisone butyrate or 0.005% ﬂu-
ticasone) as measured by the Patient’s Assessment of Global
Response (‘much better’) and the Physician’s Global Evaluation
of Clinical Response (‘cleared or excellent improvement’). While
the incidence of skin burning was increased with tacrolimus
treatment in both adult and paediatric patients, levels of skin
infection, skin erythema and rash were comparable between
treatments. Data from four trials comparing tacrolimus ointment
with 1% pimecrolimus cream were suitable for inclusion in meta-
analysis (paediatric, n = 793; adult, n = 731). From week three of
treatment onwards, tacrolimus at both doses was superior to
treatment with 1% pimecrolimus cream in both paediatric and
adult populations. Considering safety, the incidence of skin infec-
tion, pruritis, erythema and pain were comparable between treat-
ments. CONCLUSIONS: In the majority of included RCTs,
tacrolimus ointment at a dose of 0.03% or 0.1% demonstrates
superior efﬁcacy compared with corticosteroids or 1% pimecroli-
mus cream in the treatment of both paediatric and adult AD
patients. Adverse events were predictable in nature and with the
exception of skin burning did not differ between treatments.
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OBJECTIVES: To investigate the comparative incidence of
hyperaemia of all prostaglandin glaucoma treatments in avail-
able randomised controlled trials (RCTs). METHODS: A sys-
tematic review searching MEDLINE, EMBASE, Cochrane
Central and conference proceedings until March 2007 for RCTs
of adults with primary open-angle glaucoma (POAG) and/or
ocular hypertension (OH) receiving prostaglandin treatment.
Active comparison parallel RCTs longer than three months were
included. Results were pooled through ﬁxed effects meta-
analyses. RESULTS: We found 13 RCTs (7 for each prostaglan-
din comparison) including 2364 patients in total. The median
duration of trials was 19.5 weeks (range: 12–52 weeks). The
average incidence of hyperaemia was 35% (95% CI: 33%–37%)
in patients receiving prostaglandin treatments (travoprost and
bimatoprost = 44%, latanoprost = 27%). Comparing bimato-
prost versus latanoprost, the pooled risk ratio using ﬁxed effects
models for having hyperaemia was 1.83 (95% CI: 1.54–2.18),
travoprost vs. latanoprost was 1.52 (95% CI: 1.28–1.79);
bimatoprost v.s. travoprost was 1.23 (95% CI: 1.03–1.46). These
equate to one more case of hyperaemia for every 5 patients
treated with bimatoprost rather than latanoprost, every 6 treated
with travoprost rather than latanoprost, and every 8 treated with
bimatoprost rather than travoprost. Sensitivity analysis using a
random effects model did not alter the ﬁndings. Of the included
RCTs, eight reported hyperaemia severity on a discrete scale of
0 to 3, with some reporting additional increments of 0.5. The
variability in scales and statistics reported prevented meta-
analysis of these data. CONCLUSIONS: Hyperaemia was
common, affecting more than a third of patients treated with
prostaglandins. However, there is a lack of consistent reporting
among RCTs to address its burden. Compared to latanoprost
treated patients, bimatoprost and travoprost incurred an addi-
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